PI-103

PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。

価格 在庫  
USD 168 あり
USD 185 あり
USD 340 あり
USD 466 あり

PI-103 化学構造
分子量: 348.36

高品質保証

カスタマーフィードバック(4)

Quality Control & MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • PI-103のメカニズム

製品の説明

生物活性

製品説明 PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。
ターゲット p110α p110β p110δ p110γ mTOR DNA-PK
IC50 2 nM 3 nM 3 nM 15 nM 30 nM 23 nM [3]
In vitro試験 PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BE Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTJe4JyOC16IN88US=> NIDWSYgzPC92OD:3NkBp MoK3bY5lfWOnczD0bY1mNSCjbnSgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7obYJqfGmxbjDvckBPSiClZXzsJIdzd3e2aB?= NIfQTm0zPjJ{NE[4NS=>
SH-SY5Y Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml36NE05KM7:TR?= M1nueVI1NzR6L{eyJIg> MoW5bY5lfWOnczD0bY1mNSCjbnSgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7obYJqfGmxbjDvckBPSiClZXzsJIdzd3e2aB?= NYPCdWxlOjZ{MkS2PFE>
SH-SY5Y  M3SzWWFxd3C2b4Ppd{BCe3OjeR?= NYT2SZp2OSEQvF2= NWXjTohHOC53LUK0JIg> NEXUbmh{\W6|aYTpfoV{KG6ndYLvZoxie3SxbXGgZ4VtdHNidH:g[I95d3K3YnnjbY4ucW6mdXPl[EBieG:ydH;zbZM> MlPKNlYzOjR4OEG=
G 35 SC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[zSGQxNjB3LUKwJO69VQ>? NXLJPXNoOjRxN{KgbC=> NXf4W4VnTE2VTx?= NH3GbWtqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 Mmi5NlYyOjF{NUG=
G 38 SC NULOWoEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvPfod7OC5yNT2yNEDPxE1? MmT6NlQwPzJiaB?= Mn;TSG1UVw>? MnHXbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? MlfINlYyOjF{NUG=
G 40 SC Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDBfYoxNjB3LUKwJO69VQ>? MnW3NlQwPzJiaB?= NFGwbG5FVVOR NF\DZ3pqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 NYflfG9{OjZzMkGyOVE>
G 35 DC NVj2b|ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvNUHMxNjB3LUKwJO69VQ>? NWDIfYhIOjRxN{KgbC=> MXPEUXNQ MWDpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MnfKNlYyOjF{NUG=
G 38 DC NWPEU2JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWweox5OC5yNT2yNEDPxE1? NILLOJgzPC95MjDo NXzKeJZ6TE2VTx?= M4PzfIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NFLM[XEzPjF{MUK1NS=>
G 40 DC NUe3fZZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfKSZAxNjB3LUKwJO69VQ>? NU[5NpQ3OjRxN{KgbC=> NH3IUGZFVVOR NUmwWZIxcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= MojsNlYyOjF{NUG=
RD MV7BdI9xfG:|aYOgRZN{[Xl? NX25VGZWOS9zLkWvNkDPxE1? NHfp[HQ4OiCq MYjpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> NWLWPG5tOjV5NEmzO|g>
TE381.T MYnBdI9xfG:|aYOgRZN{[Xl? MXyxM|EvPS9{IN88US=> MmXzO|IhcA>? MVTpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> MV6yOVc1QTN5OB?=
RMS13 NYnz[YxkSXCxcITvd4l{KEG|c3H5 M17UWFEwOS53L{Kg{txO M2WwcFczKGh? MYjpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> NX35OFVyOjV5NEmzO|g>
RH30  MWHBdI9xfG:|aYOgRZN{[Xl? MWSxM|EvPS9{IN88US=> MVe3NkBp MVzpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> MU[yOVc1QTN5OB?=
VJ NUDnbYJHSXCxcITvd4l{KEG|c3H5 NETvdIEyNzFwNT:yJO69VQ>? NITjTVY4OiCq NUHRcHVlcW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDHRW5VPjF? NUf6XIk1OjV5NEmzO|g>
HS578T MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mn7sNE0{KM7:TR?= M3H0VFczKGh? MWHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MYiyOVczOTRzOR?=
BT549 M3r5RWNmdGxiVnnhZoltcXS7IFHzd4F6 NIr1cHUxNTNizszN NUPXNWJQPzJiaB?= M4XyXIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NFHBRXgzPTd{MUSxPS=>
MDA-MB-231 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3\RdlAuOyEQvF2= NH3MNGE4OiCq NHmyTXZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MV[yOVczOTRzOR?=
MDA-MB-468 NUm0e2luS2WubDDWbYFjcWyrdImgRZN{[Xl? M33zSFAuOyEQvF2= MlfrO|IhcA>? M2fsNYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NH7xOogzPTd{MUSxPS=>
MDA-MB-436 MoThR4VtdCCYaXHibYxqfHliQYPzZZk> Ml\QNE0{KM7:TR?= NXzSdZZ{PzJiaB?= MkPYbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MnnHNlU4OjF2MUm=
SUM149PT M17H[GNmdGxiVnnhZoltcXS7IFHzd4F6 NXLxendmOC1|IN88US=> NH3tUG04OiCq NYG3SGhPcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MnGzNlU4OjF2MUm=
MDA-MB-468 M{m5dWZ2dmO2aX;uJGF{e2G7 NYHzfWs6OC5yMT2xNEDPxE1? NETFTXQzPCCq MWLkc5dvemWpdXzheIV{KHSqZTDs[ZZmdHNib3[g{tIuXHKFUEGsJIMuVXmlIHHu[EBkgWOuaX6gSUBxem:2ZXnud:Kh M2Dw[VI2PzJzNEG5
MDA-MB-231 NHHXOIVHfW6ldHnvckBCe3OjeR?= M4\EZVAvODFvMUCg{txO Mm\nNlQhcA>? M{\wToRwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB? NUjWNIVYOjV5MkG0NVk>
HS578T NWfqTIlQTnWwY4Tpc44hSXO|YYm= NUnjV5dnOC5yMT2xNEDPxE1? M{\uVlI1KGh? Mmf5[I94dnKnZ4XsZZRmeyC2aHWgcIV3\Wy|IH;mJO6zNVS{Q2CxMEBkNU27YzDhcoQh[3mlbHnuJGUheHKxdHXpcpPDqA>? NUDwWZNlOjV5MkG0NVk>
SW872 MWHGeY5kfGmxbjDBd5NigQ>? M{XyTlAvODFvMD61JO69VQ>? M4PMUFI1KGh? MXfy[YR2[2W|IFHLWEBxcG:|cHjvdplt[XSrb36gLJBCU1RrIHHu[EA1TUKSMTDwbI9{eGixconsZZRqd25iKIC0SWJROSliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= NVXUb3VqOjR4OUW2N|I>
SW982 MkHjSpVv[3Srb36gRZN{[Xl? NWL3W|F5OC5yMT2wMlUh|ryP MnjCNlQhcA>? M3SzRpJm\HWlZYOgRWtVKHCqb4PwbI9zgWyjdHnvckApeEGNVDmgZY5lKDSHQmCxJJBpd3OyaH;yfYxifGmxbjCodFRGSlBzKTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg MlHNNlQ3QTV4M{K=
SW872 MUjBdI9xfG:|aYOgRZN{[Xl? Mn64NE4xOS1yLkWg{txO NXzKTlhbPDhiaB?= MYnpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 Mn;vNlQ3QTV4M{K=
SW982 NVXoWndOSXCxcITvd4l{KEG|c3H5 NFnaV2QxNjBzLUCuOUDPxE1? NFLvSVE1QCCq MnPpbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MYCyOFY6PTZ|Mh?=
AGS HG NXv2[GJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwNkigxtEhOC5yM{Gg{txO NFr3ToozPDV7N{S3PC=>
AGS LG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLTUpVKSzVyPUCuNFUhyrFiMD6wNFEh|ryP MYWyOFU6PzR5OB?=
HGC27 HG MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fzO2lEPTB;MD6zPEDDuSByLkCyNkDPxE1? MojkNlQ2QTd2N{i=
HGC27 LG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMEKgxtEhOC5yMESg{txO M3:zZ|I1PTl5NEe4
MKN45 HG NEHkOZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LTSWlEPTB;MT6wNUDDuSByLkC1NUDPxE1? MkS2NlQ2QTd2N{i=
MKN45 LG NH\yZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwOEegxtEhOC5yM{Cg{txO MlrqNlQ2QTd2N{i=
NUGC4 HG MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrFTWM2OD1zND6wJOKyKDNwOUGzJO69VQ>? NVfxOYp2OjR3OUe0O|g>
NUGC4 LG NFvL[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYqyUnpoUUN3ME2xOE4xKMLzIEWuN|IyKM7:TR?= MmnqNlQ2QTd2N{i=
A549 NEXwXGhHfW6ldHnvckBCe3OjeR?= M3ryV|AvOjVxMD61M|Eh|ryP M1jEO|I1KGh? M3jCVolvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2yrZ3j0cJk> NGT1XZMzPDN3MUSyOS=>
H460 MnvUSpVv[3Srb36gRZN{[Xl? NXLrW4pqOC5{NT:wMlUwOSEQvF2= NHr1UVgzPCCq MWPpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNtcWeqdHz5 NFPhWYkzPDN3MUSyOS=>
H661 MnfCSpVv[3Srb36gRZN{[Xl? M3\LTVAvOjVxMD61M|Eh|ryP MWmyOEBp MlfsbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 NU\1W4c6OjR|NUG0NlU>
SAS Mlv3SpVv[3Srb36gRZN{[Xl? NUnJc2hFOC5{NT:wMlUwOSEQvF2= MYKyOEBp MWrpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? NYDRTIZDOjR|NUG0NlU>
UT5 Mm[xSpVv[3Srb36gRZN{[Xl? M4fHO|AvOjVxMD61M|Eh|ryP Mn3TNlQhcA>? MVfpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? NIjjNVQzPDN3MUSyOS=>
FaDu MmDPSpVv[3Srb36gRZN{[Xl? MmXvNE4zPS9yLkWvNUDPxE1? MUGyOEBp MVXpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? NXzNT|gyOjR|NUG0NlU>
RD MXzBdI9xfG:|aYOgRZN{[Xl? MY[xM|EvPS9{IN88US=> MmO2O|IhcA>? NIDIOJZFVVOR NGfDTmVqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 M4DaUFI{Pjh2OUK1
TE671 M3P2UGFxd3C2b4Ppd{BCe3OjeR?= NVG4SIdoOS9zLkWvNkDPxE1? NYT1V5dCPzJiaB?= MlzTSG1UVw>? NGfGZZpqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIGXPNVI3 M3rwN|I{Pjh2OUK1
RH30  NVO2W3FzSXCxcITvd4l{KEG|c3H5 NU[0ZpE1OS9zLkWvNkDPxE1? MXK3NkBp MXvEUXNQ M4PGeYlv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiVV:xNlY> NF\zOmUzOzZ6NEmyOS=>
RMS13 NHTqc5ZCeG:ydH;zbZMhSXO|YYm= NGLlTGQyNzFwNT:yJO69VQ>? NUTtVIFIPzJiaB?= NWLUZW5CTE2VTx?= MlS2bY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> M1zKZ|I{Pjh2OUK1
SUM149PT M4DDcWNmdGxiVnnhZoltcXS7IFHzd4F6 NWP0eoJxOC5|IN88US=> M3zFOlczKGh? Ml7a[Y5p[W6lZYOgZ5l1d3SxeHnjJIVn\mWldIOgc4YhWEl|Sz;BT3QheGG2aIfhfUBqdmirYnn0c5J{ MX:yN|YxOTB5NB?=
MDA-MB-468 MnzuR4VtdCCYaXHibYxqfHliQYPzZZk> NITFNWIxNjNizszN MYG3NkBp MX\lcohidmOnczDjfZRwfG:6aXOg[YZn\WO2czDv[kBRUTONL1HLWEBx[XSqd3H5JIlvcGmkaYTvdpM> MnTGNlM3ODFyN{S=
MDA-MB-231 M{DNPGNmdGxiVnnhZoltcXS7IFHzd4F6 MmTHNE4{KM7:TR?= MXq3NkBp NIHUWGhmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? NIfU[5MzOzZyMUC3OC=>
SY5Y NFvv[5NHfW6ldHnvckBCe3OjeR?= Mn;kNU42NzJwNT:1JO69VQ>? MnT4NlQhcA>? MnnKbY5lfWOnczDHNeKh[2WubD3jfYNt\SCjcoLld5Qh[W6mIHHwc5B1d3Orcx?= MV6yN|M4QDN2MR?=
SKNBE(2c) MYLGeY5kfGmxbjDBd5NigQ>? NITVeZcyNjVxMj61M|Uh|ryP NXnkZXlrOjRiaB?= M{SySIlv\HWlZYOgS|HDqGOnbHytZ5lkdGViYYLy[ZN1KGGwZDDhdI9xfG:|aYO= NUXNWXBjOjN|N{izOFE>
RD NHHwRohCeG:ydH;zbZMhSXO|YYm= NYrVc|FpOyEEtV2= NUm5VWVJOTJiaB?= NIfvbY5FVVOR NYTvbWpne2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> MlvsNlM{ODB6MEm=
TP5014 NHPQZ4JCeG:ydH;zbZMhSXO|YYm= NW\4SnI2OyEEtV2= NF7QW2MyOiCq M4P1W2ROW09? NWnHZXV6e2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> MYiyN|MxODhyOR?=
HT1080 MXvBdI9xfG:|aYOgRZN{[Xl? MV6zJOK2VQ>? NYjSWlhQOTJiaB?= NVTQVop5TE2VTx?= NVnvfWtze2Wwc3n0bZpmeyCURDDj[YxteyC2bzDEU3gucW6mdXPl[EBieG:ydH;zbZM> NUe3NGxWOjN|MEC4NFk>
A549 MXHGeY5kfGmxbjDBd5NigQ>? M33x[FAuOy5|IN88US=> NYnn[3dsPzJiaB?= NELjVHlqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? NWTocHBSOjN{NUm1PVE>
HCC827 NF:yO21HfW6ldHnvckBCe3OjeR?= MlnaNE0{NjNizszN MnTNO|IhcA>? MoTBbY5lfWOnczDjc41xdGW2ZTDkc5dvemWpdXzheIlwdiCxZjDwRWtV M4rGZ|I{OjV7NUmx
H3122 MWXGeY5kfGmxbjDBd5NigQ>? NWDNblZJOC1|LkOg{txO NWKwdHloPzJiaB?= M{DSdolv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? MlfDNlMzPTl3OUG=
TALL-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2x5qCK|ryP MoD2O{Bl MXrk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NFL2c4QzOzB|OEK3Ny=>
HPB-ALL NH[xbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3tNgKBkc7:TR?= MUm3JIQ> M3HXfoRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MViyN|A{QDJ5Mx?=
DND41 M{XSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWx5qCK|ryP MX:3JIQ> MWHk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MUWyN|A{QDJ5Mx?=
SUP-T1 NWPxbWFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHmXVEy6oDLzszN MUS3JIQ> MkTM[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MkHoNlMxOzh{N{O=
PEER MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrhe2Ey6oDLzszN NHPoU2M4KGR? M2XH[YRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? M2HLb|I{ODN6Mkez
ALL-SIL NEDS[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jxTVHjiIoQvF2= MlPlO{Bl M3raS4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MWSyN|A{QDJ5Mx?=
KE37 NEi3WphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGzNgKBkc7:TR?= NWi5U4FkPyCm NUfm[GNn\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 Mo\0NlMxOzh{N{O=
Karpas-45 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHTZooy6oDLzszN MlfLO{Bl NVGyU5Bn\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MV[yN|A{QDJ5Mx?=
RPMI-8402 NF:xRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\2NgKBkc7:TR?= Mmr0O{Bl M17oO4Rm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? M{TPR|I{ODN6Mkez
Jurkat NF62VZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYix5qCK|ryP M3:3[|ch\A>? M1TMVYRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? M{fHcVI{ODN6Mkez
MOLT-4 NHzLXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYWx5qCK|ryP NHj2U3Q4KGR? MUXk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MnfuNlMxOzh{N{O=
PF-382 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSx5qCK|ryP M33L[Vch\A>? MWHk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MV[yN|A{QDJ5Mx?=
CCRF-CEM M1S3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPENgKBkc7:TR?= MoXGO{Bl MWnk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MXqyN|A{QDJ5Mx?=
LOUCY M3zENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX1Wmsy6oDLzszN M1y4SVch\A>? Mk\m[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MUWyN|A{QDJ5Mx?=
MOLT-16 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nYZlHjiIoQvF2= MX[3JIQ> MX3k[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NGnzOI4zOzB|OEK3Ny=>
MM1S NFHxeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTIT21VOC1{IN88US=> MVeyOEBp MVrJR|UxRTBwNTFOwG0> NI\vdFAzOjh{OUKzOC=>
NCI-H929 NXfpNI11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX2T3MxNTJizszN MnnRNlQhcA>? NFPxOlFKSzVyPUCuNlUh|ryP MV:yNlgzQTJ|NB?=
KMS12-BM  NYrCbFB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDjZXQxNTJizszN MlfSNlQhcA>? M1\C[GlEPTExvK6yJO69VQ>? NUH6b417OjJ6MkmyN|Q>
MDA-MB-436 NHy4SoFHfW6ldHnvckBCe3OjeR?= NFHP[VAyKM7:TR?= NVrNZmtjOjRiaB?= MXzy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW NGrMbFMzOjR6OEW5NC=>
SUM149PT NVjC[nl1TnWwY4Tpc44hSXO|YYm= NUDIfIdwOSEQvF2= M13DW|I1KGh? NEP6eVJz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU NGfPTHQzOjR6OEW5NC=>
SUM1315MO2 NXe0R5c3TnWwY4Tpc44hSXO|YYm= MVmxJO69VQ>? MmLrNlQhcA>? M4nBN5Jm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2S= NWX0c3dpOjJ2OEi1PVA>
HCC1937 MXPGeY5kfGmxbjDBd5NigQ>? MYSxJO69VQ>? NXfMb5o2OjRiaB?= MUHy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW NIXxS2kzOjR6OEW5NC=>
HCC827 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK2bZRlOC1|IN88US=> NGCye4E4OiCq NUTZPXpRUUN3ME2wMlMh|ryP NHrBXoYzOTJ{MES3OC=>
PC-9  M2rjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPzNE0{KM7:TR?= NUjWZWNyPzJiaB?= Mkf2TWM2OD1yLkig{txO MonONlEzOjB2N{S=
LN229 M2TYeWZ2dmO2aX;uJGF{e2G7 MlTYNUDPxE1? M{Pxe|Q5KGh? NWDrRVJGcW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= MYiyNVA3Ojl7Mx?=
U87 MUPGeY5kfGmxbjDBd5NigQ>? MX2xJO69VQ>? MYC0PEBp MYrpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v M{G5[lIyODZ{OUmz
U373 NFHlfWNHfW6ldHnvckBCe3OjeR?= M2nacVEh|ryP MV:0PEBp NY\jepM2cW6mdXPld{BifXSxcHjh[49{d22nIH\vdo1ifGmxbh?= NVTRT244OjFyNkK5PVM>
SF767 MVvGeY5kfGmxbjDBd5NigQ>? M3jPV|Eh|ryP NXTJTHU6PDhiaB?= NHPDTnpqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w NUTmUZVtOjFyNkK5PVM>
Mel-Juso NFTFUIlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUWwMlAy6oDVMUFihKnPxE1? NGriWVE4OiCq MVnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MYCyNVA1QDd6NR?=
518A2  MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYW3R2E1OC5yMfMAl|Ex6oDLzszN M372TVczKGh? MXzpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MlHSNlExPDh5OEW=
Mel-Juso  M2TNfGZ2dmO2aX;uJGF{e2G7 NV;hSplNOC5yMEJihLMy6oDLzszN M4XUTlI1KGh? Mmewd5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= NHG2S2wzOTB2OEe4OS=>
518A2 MkHDSpVv[3Srb36gRZN{[Xl? NITRR|MxNjByMfMAl|HjiIoQvF2= Mmj1NlQhcA>? MlGyd5VxeHKnc4Pld{BxcG:|cHjvdplt[XSrb36gc4YheGixc4DoZZRq\HmuIHnuc5NqfG:uIEOtb4lv[XOnIHTve45{fHKnYX2geIFz\2W2cx?= MoLRNlExPDh5OEW=
PC3  M2fmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD5O5BWOjSq NWHQNlBDT0l3MNMgQUAyODBibl2= MlW0NlA2PTFyNkG=
U87MG NH\wbGVHfW6ldHnvckBCe3OjeR?= Mn65NE4yNTFizszN NX3VeGN2OjUkgJnoxsA> NHnSUHdFVVOR NXzmb2dPcW6qaXLpeJMhWEl|Sz3t[YRq[XSnZDDzbYdv[Wyrbne= NXTKRmMzOTl4M{O2PFM>
U138MG M2rLWGZ2dmO2aX;uJGF{e2G7 M3zGNlAvOS1zIN88US=> M3noO|I16oDLaNMg MYXEUXNQ NGLsTYdqdmirYnn0d{BRUTONLX3l[IlifGWmIIPp[45idGmwZx?= NV7kSW1LOTl4M{O2PFM>
U118MG NYq0R2ZtTnWwY4Tpc44hSXO|YYm= NG[1[JYxNjFvMTFOwG0> NYHYSlR5OjUkgJnoxsA> MUPEUXNQ NE[yOGdqdmirYnn0d{BRUTONLX3l[IlifGWmIIPp[45idGmwZx?= M4[1VVE6PjN|Nkiz
U87MG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG4VHJ5UUN3ME2wMlE1KM7:TR?= NWD0WlNyOTl3OESyNlc>
IGROV-1 NXLtcYlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvI[GZKSzVyPUCuNFYh|ryP NGHUeZMyQTV6NEKyOy=>
DETROIT562 MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vzNWlEPTB;MD6xN{DPxE1? MkH3NVk2QDR{Mke=
PC3  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwMUCg{txO MXOxPVU5PDJ{Nx?=
SKOV-3 NWTKPWxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rScmlEPTB;MD6xNkDPxE1? M1\GPFE6PTh2MkK3
HUVEC MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PUUmlEPTB;MD6wPEDPxE1? MVKxPVU5PDJ{Nx?=
UCH-1  NHvtW3dHfW6ldHnvckBCe3OjeR?= NFTHUW4xNTVizszN M1zZSolvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiYn;0bEBCU1RiYX7kJI1VV1JiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NY\TcHdPOTl3Mki0OFE>
UCH-1  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[wMlAyNTFyIN88US=> NHm2fpk3KGR? M2ruSIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iZH;z[UBl\XCnbnTlcpRtgQ>? NIr0SYEyQTV{OES0NS=>
UCH-1  MmTlRZBweHSxc3nzJGF{e2G7 Ml\wNE4yNTFyIN88US=> M4W2S|I1KGh? NVvGcJhwTE2VTx?= NUnRT5pycW6mdXPld{BieG:ydH;zbZM> M3nvTFE6PTJ6NESx

... Click to View More Cell Line Experimental Data

In vivo試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
臨床試験
特集 The first potent, synthetic mTOR inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

細胞アッセイ: [2]

細胞株 U87MG cells
濃度 0.5 μM
反応時間 24 hours
実験の流れ U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

動物実験: [2]

動物モデル 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
製剤 50% DMSO
投薬量 5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download PI-103 SDF
分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

カスタマーフィードバック (4)


Click to enlarge
Rating
Source Mol Carcinog, 2012, 52, 667-75 . PI-103 purchased from Selleck
Method Western blot
Cell Lines MCF7 cells
Concentrations 0-1 μM
Incubation Time 24 h
Results In BRCA1-KD MCF7 cells, treatment of PI-103, a PI3K/mTOR inhibitor, abolished phosphorylation of AKT and its substrate GSK3b, in a dose dependent manner (Figure A). Treatment of PI-103 reduced the phosphorylation of AKT in all BRCA1 mutant breast cancer cells tested (Figure B). Phosphorylations of downstream targets of AKT, such as phospho-GSK3b (S9) and phospho-BAD(S112) were also reduced by PI-103 treatment. Phosphorylation of mTOR at S2448, which is also known to be phosphorylated by AKT, was also reduced by PI-103 resulting in reduced phosphorylation of S6 ribosomal protein at S235/236 (Figure B). The effect of PI-103 was much more potent than LY294002 in MDA-MB-436 cells (Figure B)

Click to enlarge
Rating
Source Mol Carcinog, 2012, ahead of print. PI-103 purchased from Selleck
Method MTT assay
Cell Lines MCF7 cells
Concentrations 0.01-1 μM
Incubation Time 48 h
Results Knockdown of BRCA1 can sensitize the MCF7 cells to Perifosine in a dose-dependent manner (Figure A). BRCA1-KD also sensitizes the MCF7 cells to dual PI3K/mTOR inhibitors, such as PI-103 or BEZ235 (Figure B, D). Another inhibitor, PIK-75 which specifically inhibits PI3Ka and PI3Kg, but not mTOR, also showed similar effects on proliferation of BRCA1-KD MCF7 cells (Figure C).

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 24 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in Breast cancer cells.

Click to enlarge
Rating
Source Saraswati Sukumar of Johns Hopkins University School of Medicine, PI-103 purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations
Incubation Time 1 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in T47D cells.

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032 is a potent, next-generation PI3K inhibitor targeting PI3K alpha.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • PI-3065

    PI-3065 is a selective p110δ inhibitor with IC50 of 15 nM, >70-fold selectivity over other PI3K family members.

  • LY294002

    LY294002は、p110α、p110δとp110βのPI3K阻害剤で、IC50 がそれぞれ 0.5 μM、0.57 μM、0.97 μMです。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) は選択の自噬とリン酸イノシトール3キナーゼ(キナーゼ)阻害剤、Vps34 と PI3Kγ に作用する時、 IC50 がそれぞれ 25 nM と 60 nM になる。自動食物胞の形成を妨害すること。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は、2.5nMのIC50によるp110δの選択的なPI3KクラスI阻害剤です。

  • Wortmannin

    ワートマニンはミオシン軽鎖キナーゼ(MLCK)のマルチターゲットの阻害剤、IC50がぞれぞれ0.17μMと3nMになる。自動食物胞の形成を妨害すること。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は、p110α、p110β、p110δとp110γの選択的なPI3K阻害剤で、IC50 がそれぞれ 52-99 nM、166 nM、 116 nM、 262 nMです。

最近チェックしたアイテム

Tags: PI-103を買う | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ